Gradient Denervation Technologies - Company Research Report
Company Overview
- Name: Gradient Denervation Technologies
- Mission: To develop a device-based, minimally invasive solution for treating heart failure patients with associated pulmonary hypertension, aiming to improve cardiovascular health.
- Founded: February 2020
- Founders: Dr. Swami Gnanashanmugam, Dr. Jeffrey Feinstein
- Key People/Management:
- CEO: Martin Grasse
- CFO: Greg Mann
- CTO: David Amaoua
- COO: Julie Messer
- Board of Directors:
- Evan Castiglia
- Lisa Wipperman Heine
- Martin Grasse (CEO/Director)
- Juan Pablo Mas
- Mano Iyer
- Sylvain Sachot, PhD
- Headquarters: 5 rue Gardenat Lapostol, 92150 Suresnes, France
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: Developing a minimally-invasive device solution to treat pulmonary hypertension in patients with heart failure.
Products
- Product Name: Pulmonary Artery Denervation System
- Description: A minimally-invasive, ultrasound-based device designed for treating pulmonary hypertension, particularly for patients with heart failure.
- Key Features:
- Uses therapeutic ultrasound energy to perform denervation around the pulmonary artery.
- Aims to down-regulate the sympathetic nervous system's input, reducing pulmonary vascular resistance.
- Designed for investigational use and currently under clinical development.
Recent Developments
- FDA-Approved Study: On March 6, 2024, Gradient was approved by the FDA to initiate the PreVail-PH2 Early Feasibility Study in the US, enrolling heart failure patients with WHO Group 2 Pulmonary Hypertension.
- Series A Financing: Closed a €14 million Series A funding round on September 7, 2023, led by Sabadell Asabys, with participation from Thuja Capital and Sofinnova Partners, aimed at advancing clinical development.
- First-in-Human Study: Enrolled the first patient in a first-in-human clinical study on June 1, 2023, conducted in Georgia, aimed at testing the pulmonary artery denervation technology.
- CEO Appointment: Martin Grasse was appointed as the CEO on April 7, 2022, bringing over 15 years of experience in the medical device industry.
- Seed Funding: Raised €3.5M in seed funding on September 17, 2020, from Sofinnova Partners to support the technology's development.
- Grants and Recognition:
- EIT Health Catapult: 2020 Medtech 3rd place winner.
- i-Lab 2020 Laureat.
Gradient Denervation Technologies continues to focus on providing innovative solutions to treat pulmonary hypertension, moving towards significant regulatory and clinical milestones.
